Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. D. Boral Capital’s price objective would indicate a potential upside of 356.62% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock opened at $2.19 on Tuesday. The business’s 50 day moving average price is $2.89 and its 200 day moving average price is $3.03. The company has a market cap of $70.47 million, a price-to-earnings ratio of -5.62 and a beta of 0.90. Anixa Biosciences has a one year low of $2.14 and a one year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, analysts predict that Anixa Biosciences will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently modified their holdings of the business. Tyler Stone Wealth Management raised its position in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Westside Investment Management Inc. raised its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares during the period. Concorde Asset Management LLC acquired a new position in Anixa Biosciences during the 2nd quarter worth about $31,000. Finally, Virtu Financial LLC purchased a new position in Anixa Biosciences during the 3rd quarter valued at about $34,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.